Common supplement may shield kidneys from chemo damage
NCT ID NCT07156786
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether N-Acetylcysteine (NAC), a common supplement, can protect kidney function in cancer patients receiving cisplatin chemotherapy. 72 adults will take either NAC or a placebo for seven days around their chemo session. Researchers will measure kidney injury markers in urine and blood to see if NAC helps prevent damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- N-Acetylcysteine (NAC)
- What this could lead to
- If it works, this could point toward a simple way to reduce kidney damage from cisplatin chemotherapy, helping patients tolerate treatment better.
- What could go wrong
- This is a small, early-phase trial with only 72 participants. The results may not apply to all patients, and NAC may not provide significant protection or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACETYLCYSTEINE ADVERSE REACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which emergency dialysis saves more lives? a new study investigates
- A simple sensor on the back could warn of kidney danger during heart surgery
- Can a common blood thinner be safe for ICU patients with liver issues?
- A urine test that could foresee kidney danger in the ICU
- Which citrate solution minimizes metabolic chaos in kidney therapy?
- A wearable sensor might spot kidney danger before it strikes